Chemical: Drug
pamidronate

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for pamidronate

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs11730582 NC_000004.11:g.88896421T>C, NC_000004.12:g.87975269T>C, NG_030362.1:g.4620T>C, NM_000582.2:c.-546T>C, NM_001040058.1:c.-546T>C, NM_001040060.1:c.-546T>C, NM_001251829.1:c.-546T>C, NM_001251830.1:c.-696T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs12458117 NC_000018.10:g.62360215G>A, NC_000018.9:g.60027448G>A, NG_008098.1:g.39901G>A, NM_001270949.1:c.616+166G>A, NM_001270950.1:c.616+166G>A, NM_001270951.1:c.616+166G>A, NM_001278268.1:c.574+166G>A, NM_003839.2:c.616+166G>A, NM_003839.3:c.616+166G>A, XM_005266777.1:c.616+166G>A, XM_011526244.1:c.631+166G>A, XM_011526245.1:c.508+166G>A, XR_935263.1:n.646+166G>A, rs56781861
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1800012 NC_000017.10:g.48277749C=, NC_000017.10:g.48277749C>A, NC_000017.11:g.50200388C=, NC_000017.11:g.50200388C>A, NG_007400.1:g.6252G=, NG_007400.1:g.6252G>T, NM_000088.3:c.104-441G=, NM_000088.3:c.104-441G>T, XM_005257058.1:c.104-441G=, XM_005257058.1:c.104-441G>T, XM_005257058.3:c.104-441G=, XM_005257058.3:c.104-441G>T, XM_005257059.1:c.104-441G=, XM_005257059.1:c.104-441G>T, XM_005257059.3:c.104-441G=, XM_005257059.3:c.104-441G>T, XM_011524341.1:c.104-441G=, XM_011524341.1:c.104-441G>T, rs58312232, rs8179177
C > A
SNP
No VIP available CA No Variant Annotations available
rs1934951 NC_000010.10:g.96798548C>T, NC_000010.11:g.95038791C>T, NG_007972.1:g.35707G>A, NM_000770.3:c.1291+106G>A, NM_001198853.1:c.1081+106G>A, NM_001198854.1:c.985+106G>A, NM_001198855.1:c.1081+106G>A, XR_246073.1:n.1426+106G>A, XR_945610.1:n.1426+106G>A, rs60958510
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2073618 NC_000008.10:g.119964052G>C, NC_000008.11:g.118951813G>C, NG_012202.1:g.5332C>G, NM_002546.3:c.9C>G, NP_002537.3:p.Asn3Lys, XM_005250756.1:c.-625G>C, XM_005250756.2:c.-625G>C, rs17751701, rs60810341
G > C
SNP
N3K
No VIP available No Clinical Annotations available VA
rs243865 NC_000016.10:g.55477894C>T, NC_000016.9:g.55511806C>T, NG_008989.1:g.3726C>T, NM_001302508.1:c.-1147C>T, NM_004530.5:c.-1586C>T, rs17859818, rs2071338, rs58165103
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • APD
  • Acide pamidronique [INN-French]
  • Acido pamidronico [INN-Spanish]
  • Acidum pamidronicum [INN-Latin]
  • Pamidronate Disodium
  • Pamidronic acid
Trade Names
  • Amidronate
  • Aminomux
  • Aredia
Brand Mixture Names

PharmGKB Accession Id

PA450767

Type(s):

Drug

Description

Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. Wikipedia

Source: Drug Bank

Indication

For the treatment of moderate or severe hypercalcemia associated with malignancy

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Source: Drug Bank

Pharmacology

Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Pamidronate is not metabolized and is exclusively eliminated by renal excretion

Source: Drug Bank

Protein Binding

Approximately 54% to human serum proteins.

Source: Drug Bank

Absorption

Plasma concentration rises rapidly upon IV administration.

Source: Drug Bank

Half-Life

The mean +/- SD elimination half-life is 28 +/- 7 hours

Source: Drug Bank

Toxicity

Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood

Source: Drug Bank

Clearance

  • 107 +/- 50 mlL/min

Source: Drug Bank

Route of Elimination

Pamidronate is not metabolized and is exclusively eliminated by renal excretion.

Source: Drug Bank

Chemical Properties

Chemical Formula

C3H11NO7P2

Source: Drug Bank

Isomeric SMILES

C(CN)C(O)(P(=O)(O)O)P(=O)(O)O

Source: Drug Bank

NCCC(O)(P(O)(O)=O)P(O)(O)=O

Source: Drug Bank

Canonical SMILES

NCCC(O)(P(O)(O)=O)P(O)(O)=O

Source: Drug Bank

Average Molecular Weight

235.0695

Source: Drug Bank

Monoisotopic Molecular Weight

235.001074735

Source: Drug Bank

SMILES

NCCC(O)(P(O)(O)=O)P(O)(O)=O

Source: Drug Bank

InChI String

InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
FDPS (source: Drug Bank)
No related drugs are available.

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to pamidronate: 7

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Bone. 2016. Lindahl K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. International journal of oral and maxillofacial surgery. 2011. Katz J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bisphosphonates pathway. Pharmacogenetics and genomics. 2011. Gong Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expectations, validity, and reality in pharmacogenetics. Journal of clinical epidemiology. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and clinical risk management. 2010. English Bevin C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008. Sarasquete Maria E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis. Current medical research and opinion. 2008. Marini Francesca, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0703-4075-51
DrugBank:
DB00282
PDB:
210
KEGG Compound:
C07395
PubChem Compound:
4674
PubChem Substance:
46504823
9599
Drugs Product Database (DPD):
2246597
BindingDB:
12581
ChemSpider:
4512
HET:
210
Therapeutic Targets Database:
DAP001416
FDA Drug Label at DailyMed:
d3f15563-21af-4e0d-a9f1-1ebc596c848f

Clinical Trials

These are trials that mention pamidronate and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.